About Me
About Me
Shaji Kumar, M.D., is global epxert in treatment of Multiple Myeloma. Dr. Kumar's and his team's research activity is focused on improving treatment outcomes for patients with Myeloma and Amyloidosis, especially high-risk disease , translation of novel therapeutic targets in multiple myeloma & monoclonal gammopathies.Dr.Shaji Kumar, is named as the next Editor-in-Chief of The Hematologist: ASH News and Reports & will serve on the position from 2023 through 2025. Dr.Shaji Kumar has authored ~700 publications in clinical and translational research.Experience
0yrs
Qualification
M.D
Location
Mayo Clinic Cancer Center, Riochester, Minnesota, USA
Groups
Upcoming Webinar
Start bookmarking content to consume it later
Start bookmarking content to consume it later
Start bookmarking content to consume it later
Multiple Myeloma • 18 Min Watch
Exploring Optimal Duration of Lenalidomide Maintenance after ASCT
Best evidence for Lenalidomide maintenance after ASCT came from Meta-analysis of 3 trials (McCarthy et al, JCO 207) confirmed significant OS benefit w...
0
0
Multiple-Myeloma • 22 Min Watch
Importance of identifying High Risk Patients in Multiple Myeloma
N/A
2
2
Myelodysplastic Syndromes • 00 Min Watch
Factors that influence treatment adherence and outcomes in MDS
Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & ...
0
0
Myelodysplastic Syndromes • 38 Min Watch
Duration of treatment does it improve outcomes Hypomethylating agents in MD
.
2
2
